Anastrozole vs Oxandrolone (Anavar)

Mechanism

Anastrozole is a potent, selective, non-steroidal third-generation aromatase inhibitor that competitively binds the heme group of cytochrome P450 aromatase (CYP19A1), blocking the conversion of testosterone to estradiol and androstenedione to estrone. In men on TRT, this reduces circulating estradiol by 50-80%, shifting the testosterone-to-estradiol ratio favorably. Estrogen suppression releases hypothalamic negative feedback, increasing GnRH, LH, and FSH secretion in non-TRT contexts. Complete estrogen ablation is detrimental to bone density, lipid metabolism, and cognitive function.

Standard Dosing

Research indicates 0.25-0.5 mg twice weekly as a TRT adjunct for estrogen management. Stand-alone hypogonadism: 1 mg twice weekly.

Timing

Take on testosterone injection days or the day after when aromatization peaks. Consistent schedule for stable estradiol control.

Cycle Duration

Ongoing as needed alongside TRT. Reassess every 3-6 months with estradiol labs. Goal is minimal effective dose.

Side Effects

• Joint pain and stiffness (from excessive estrogen suppression)
• Bone density loss with chronic use
• Lipid profile worsening (HDL suppression)
• Fatigue and brain fog (from over-suppression of estradiol)
• Mood disturbances and depression
• Hot flashes
• Decreased libido (if estradiol drops below ~15 pg/mL)

Contraindications

• Premenopausal women
• Known hypersensitivity to anastrozole
• Pre-existing severe osteoporosis (estrogen suppression worsens bone loss)
• Children (may affect bone growth plate closure)

Best Stacking Partners

Mechanism

Oxandrolone is a synthetic 17-alpha-alkylated dihydrotestosterone (DHT) derivative with a modified A-ring (replacement of C2 with an oxygen atom) that confers high anabolic-to-androgenic ratio (~10:1). It enhances protein synthesis by activating the androgen receptor while strongly binding sex hormone-binding globulin (SHBG), increasing free testosterone fraction. Oxandrolone directly stimulates phosphocreatine synthesis in skeletal muscle and has demonstrated anti-catabolic effects through cortisol receptor antagonism. In burn patients, it reverses catabolism by restoring the IGF-1/IGFBP-3 axis.

Standard Dosing

Research indicates 5-20 mg/day orally for therapeutic/recovery applications. Clinical burn protocols use 0.1 mg/kg twice daily.

Timing

Split into 2 doses (morning and evening) due to 9-hour half-life. Take with food to reduce GI discomfort.

Cycle Duration

Typical therapeutic cycles: 6-12 weeks. Clinical burn protocols have extended to 1 year+ with liver monitoring. Limit cycle length to minimize hepatic stress.

Side Effects

• Hepatotoxicity (dose and duration dependent — mild with therapeutic doses)
• Lipid profile disruption (significant HDL suppression, LDL elevation)
• Suppression of endogenous testosterone (dose dependent)
• Virilization in females at higher doses
• Headache
• Nausea
• Potential hair loss in genetically susceptible individuals

Contraindications

• Prostate cancer
• Breast cancer in males
• Hypercalcemia
• Severe hepatic impairment or active liver disease
• Nephrotic syndrome
• Pregnancy (Category X)

Best Stacking Partners